2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Cytochrome P450

Cytochrome P450

CYPs

Cytochrome P450

Related Products

PDF 2.8 MB

Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism.

Cytochrome P450 Isoform Specific Products:

Cytochrome P450 Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148595
    CYP1A1-IN-2
    		Inhibitor
    CYP1A1-IN-2 (Compound 14) is a competitive inhibitor of CYP1A1 (Ki: 1.4 μM). CYP1A1-IN-2 exhibits potent antimitotic activity and arrests cell in the G2/M phase. CYP1A1-IN-2 disrupts the microtubule and the cytoskeleton in CYP1A1-expressing breast cancer cells.
    CYP1A1-IN-2
  • HY-149769
    CP-506
    		Substrate
    CP-506 (compound 26) is an anticancer compound and a substrate for nitroreductase and CYP oxidoreductases. CP-506 has anticancer activity.
    CP-506
  • HY-137580
    N-Desmethyl Eletriptan
    N-desmethyl Eletriptan is a metabolite of Eletriptan (HY-A0039). It is formed from eletriptan primarily by the cytochrome P450 (CYP) isoform CYP3A4 in human liver microsomes.
    N-Desmethyl Eletriptan
  • HY-179686
    CYP11A1-IN-2
    		Inhibitor
    CYP11A1-IN-2 (Compound 61) is a selective cholesterol side-chain cleavage enzyme (CYP11A1) inhibitor. CYP11A1-IN-2 can inhibitor steroid biosynthesis and can be used for the research of steroid hormone-dependent cancers, such as prostate cancer.
    CYP11A1-IN-2
  • HY-N2071R
    Cedrol (Standard)
    		Inhibitor
    Cedrol (Standard) is the analytical standard of Cedrol. This product is intended for research and analytical applications. Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
    Cedrol (Standard)
  • HY-146177
    CYP3A4 enzyme-IN-1
    		Inhibitor
    CYP3A4 enzyme-IN-1 (compound 59) is a potent antibacterial agent, with a MIC of 1 μg/mL for MRSA. CYP3A4 enzyme-IN-1 exhibits low to moderate inhibitory effects on CYP1A2, CYP2E1, CYP2D6, and CYP3A4 enzymes.
    CYP3A4 enzyme-IN-1
  • HY-153989
    SOS1-IN-16
    		Inhibitor
    SOS1-IN-16 (Comp 54) is a selective inhibitor of SOS1 with an IC50 of 7.2 nM. SOS1-IN-16 has inhibitory activity of CYP3A4 when using testosterone as a substrate, with an IC50 of 8.9μM. SOS1-IN-16 can be used for cancer research.
    SOS1-IN-16
  • HY-162051
    CYP1B1-IN-6
    		Inhibitor
    CYP1B1-IN-6 (compound 19) is a fluorescence molecular probes which inhibits CYP1B1 activity. CYP1B1-IN-6 can identify tumor sites in fluorescence imaging and photoacoustic imaging modes.
    CYP1B1-IN-6
  • HY-172205
    CHL2310
    		Inhibitor
    CHL2310 is the inhibitor for CYP46A1 with an IC50 of 0.11 nM, and a Kd of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive 18F.
    CHL2310
  • HY-181629
    ZSTK3744
    		Modulator
    ZSTK3744 is an aryl hydrocarbon receptor (AhR) agonist. ZSTK3744 directly binds to AhR, upregulates the expression of AhR target genes including CYP1A1, CYP1B1 and TIPARP, and mediates cell growth inhibitory activity in triple-negative breast cancer cells. ZSTK3744 induces apoptosis in triple-negative breast cancer cells. ZSTK3744 exhibits anti-tumor activity and can be used in the research of chemoresistant triple-negative breast cancer.
    ZSTK3744
  • HY-175836
    CYP1B1-IN-12
    		Inhibitor
    CYP1B1-IN-12 is a selective cytochrome P450 1B1 (CYP1B1) inhibitor with an IC50 of 6.05 nM. CYP1B1-IN-12 demonstrates remarkable selectivity, exceeding 1600-fold and 16,000-fold over CYP1A1 and CYP1A2, respectively. CYP1B1-IN-12 can enhance Paclitaxel (HY-B0015)-mediated apoptosis and restore Paclitaxel sensitivity in A549/Taxol-resistant cells. CYP1B1-IN-12 can inhibit the epithelial-mesenchymal transition process and reduce cells migration and invasion. CYP1B1-IN-12 can be used for the research of cancer, such as non-small cell lung cancer (NSCLC).
    CYP1B1-IN-12
  • HY-146688
    SYN20028567
    		Inhibitor
    SYN20028567 is an aromatase (CYP19) inhibitor with an IC50 of 9.4 nM. SYN20028567 can be used for breast cancer research.
    SYN20028567
  • HY-158435
    P-gp inhibitor 23
    		Inhibitor
    P-gp inhibitor 23 (compound 14F) is a potent inhibitor of P-gp and CYP3A4, with the EC50 and IC50 of 28 nM and 223 nM, respectively.
    P-gp inhibitor 23
  • HY-152159
    CYP4Z1-IN-1
    		Inhibitor
    CYP4Z1-IN-1 (compound 7c) is a potent CYP4Z1 inhibitor, with an IC50 of 41.8 nM. CYP4Z1-IN-1 decreases the expression of breast CSCs stemness markers, spheroid formation, and metastatic ability as well as tumor-initiation capability in a concentration-dependent manner in vitro and in vivo.
    CYP4Z1-IN-1
  • HY-183304
    Anticancer agent 318
    		Substrate
    Anticancer agent 318 (Compound 8 (6)) is a selective anticancer agent. Anticancer agent 318 can be metabolized by CYP1A1, CYP1A2 and CYP1B1. After bioactivation, Anticancer agent 318 exerts antiproliferative activity in breast cancer cells expressing CYP1. Anticancer agent 318 can be used in the research of breast cancer.
    Anticancer agent 318
  • HY-179154
    α-Glucosidase-IN-101
    		Inhibitor
    α-Glucosidase-IN-101 (Compound 13j) is an uncompetitive α-glucosidase inhibitor, with an IC50 of 120 nM. α-Glucosidase-IN-101 properly inhibits CYP1A2, CYP2C19, and CYP2C9 isoforms of cytochrome P450. α-Glucosidase-IN-101 can be used in the research of diabetes.
    α-Glucosidase-IN-101
  • HY-A0069AS
    Doxylamine-d5
    		Activator
    Doxylamine-d5 is deuterium labeled Doxylamine (HY-A0069A). Doxylamine is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine is orally active, possessing analgesic and hypnotic activities. Doxylamine enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine can be used for the research of nausea, allergy, insomnia.
    Doxylamine-d<sub>5</sub>
  • HY-17356S1
    Fenofibrate-d4
    Fenofibrate-d4 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-d<sub>4</sub>
  • HY-W014701R
    1,4-Dihydroxy-2-naphthoic acid (Standard)
    		Agonist
    1,4-Dihydroxy-2-naphthoic acid (Standard) is the analytical standard for 1,4-Dihydroxy-2-naphthoic acid (HY-W014701). 1,4-Dihydroxy-2-naphthoic acid is an orally active aryl hydrocarbon receptor (AhR) agonist and a bifidogenic growth stimulator. 1,4-Dihydroxy-2-naphthoic acid can improve the motor dysfunction in parkinson's disease (PD) model through AhR-dependent and -independent pathways. 1,4-Dihydroxy-2-naphthoic acid exerts anti-inflammatory effects by regulating the gut microbiota (such as promoting the proliferation of Bifidobacterium) and directly regulating the host immune system. 1,4-Dihydroxy-2-naphthoic acid induces apoptosis through G0/G1 cell cycle arrest in human keratinocyte to inhibit psoriasis.
    1,4-Dihydroxy-2-naphthoic acid (Standard)
  • HY-111202R
    Pyributicarb (Standard)
    		Activator
    Proguanil (hydrochloride) (Standard) is the analytical standard of Proguanil (hydrochloride). This product is intended for research and analytical applications. Proguanil hydrochloride, an antimalarial proagent, is metabolized to the active metabolite Cycloguanil (HY-12784). Proguanil hydrochloride is a dihydrofolate reductase (DHFR) inhibitor.
    Pyributicarb (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Cytochrome P450 Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.